Precision PET imaging with POSLUMA is used to detect and localize PSMA-positive lesions in men with prostate cancer with suspected metastasis prior to initial definitive therapy and when recurrence is suspected based on elevated PSA level3,4
About POSLUMAExplore more about POSLUMA
PET=positron emission tomography; PSA=prostate-specific antigen; PSMA=prostate-specific membrane antigen.
References: 1. POSLUMA. Package insert. Blue Earth Diagnostics Ltd; 2023. 2. Wurzer A, Di Carlo D, Schmidt A, et al. Radiohybrid ligands: a novel tracer concept exemplified by 18F- or 68Ga-labeled rhPSMA inhibitors. J Nucl Med. 2020;61(5):735-742. doi:10.2967/jnumed.119.234922 3. Jani AB, Ravizzini GC, Gartrell BA, et al. Diagnostic performance and safety of 18F-rhPSMA-7.3 PET in men with suspected prostate cancer recurrence: results from a phase 3, prospective, multicenter study (SPOTLIGHT). J Urol. Published online April 26, 2023. doi:10.1097/JU.0000000000003493 4. Chapin B; LIGHTHOUSE Study Group. Diagnostic performance and safety of 18F-rhPSMA-7.3 PET in patients with newly diagnosed prostate cancer: results from a phase 3, prospective, multicenter study (LIGHTHOUSE). Poster presented at: 23rd Annual Meeting of the Society of Urologic Oncology. December 1, 2022. San Diego, CA.